Business Context and Reporting Period
Company: Aclaris Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 4, 2019
Event: Regulation FD Disclosure regarding investor meetings at the William Blair & Company 3rd Annual Late-Stage Therapeutics Conference in New York, New York.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document serves solely to disclose the occurrence of an investor presentation.
Material Changes
No material financial changes or operational updates are reported in this specific filing. The content is limited to the announcement of the conference presentation.
Guidance, Outlook, and Risks
Management Commentary: Management hosted investor meetings and provided a slide presentation (Exhibit 99.1).
Legal Status of Information: The information contained in Item 7.01 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934 and is not subject to the liability of that section. It shall not be deemed incorporated by reference in any other filings unless expressly referenced.
Key Facts for Investor Verification
- Verify the content of the investor presentation by reviewing Exhibit 99.1 attached to this filing.
- Note that the presentation materials are not legally "filed" and do not carry the same liability protections as standard SEC filings.
- Confirm the company's status as an Emerging Growth Company that has elected not to use the extended transition period for new accounting standards.
- Check subsequent filings (e.g., 10-Q or 10-K) for actual financial performance data, as this 8-K contains none.